NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

Olink: Analytical Validation (Mt Sinai)   Add to my SOP compendium

BRD ID: 3,113

Source: CIMAC-CIDC Network Tier: SOP Number of times downloaded: 483

Description

This assay analytical validation and performance report describes the methods used to validate a Olink multiplex immunoassay (specifically using an Olink Immuno-Onc Kit with a Proseek Olink Proteomics platform on a Fluidigm Biomark HD microfluidic PCR machine) to analyze RNA expression of frozen plasma (EDTA, acid citrate dextrose (ACD), sodium heparin), serum, and bone marrow specimens. The document also presents data supporting the reported accuracy, precision, analytical sensitivity and specificity, reference intervals, detection limit, measuring range, high dose hook effect, and scalability. It is used by a Cancer Immune Monitoring and Analysis Center (CIMAC) at Mount Sinai. It is a product of the CIMAC and Cancer Immunologic Data Center Network (CIMAC-CIDC Network; https://dctd.cancer.gov/ResearchNetworks/cimacs_cidc_network.htm), a Cancer Moonshot Initiative.

Documents for Download

Analytical report_Olink_05092018_Mt Sinai_508_Final.pdf [Size: 1201 KB]

Biospecimens
  • Fluid - Plasma
  • Fluid - Serum
Diagnoses
  • Neoplastic - Other
Topics
  • Platform-specific Methodology

Associated SOP Compendiums

News and Announcements

  • New Articles on the GTEx Project are Now FREELY Available!

  • Just Published!

  • April 24, 2024: Biobanking for Precision Medicine Seminar

  • More...